Emphysema Treatment Market By Treatment Type (Medication, Oxygen Therapy, Surgery), By Type (Centriacinar, Panacinar, Others), By End User (Hospitals, Homecare, Specialty Centres, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The global emphysema treatment market was valued at $6.3 billion in 2022, and is projected to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.

Emphysema is a chronic condition characterized by damage to the air sacs (alveoli) in the lungs, leading to difficulty in breathing. This damage is caused by long-term exposure to irritants, most commonly cigarette smoke. When the delicate walls of the air sacs are damaged, they lose their elasticity, making it difficult for the lungs to exhale properly. As a result, air is trapped in the lungs, causing them to inflate and leading to shortness of breath, coughing, wheezing, and other respiratory symptoms. Treatment for emphysema focuses primarily on managing symptoms and preventing further lung damage. Medications such as bronchodilators, which help to relax the muscles around the airways and improve airflow, are commonly prescribed. In more severe cases, corticosteroids are used to reduce inflammation in the lungs. Oxygen therapy may be necessary for those with low blood oxygen levels. In advanced stages, surgical options like lung volume reduction surgery or lung transplantation is considered for patients with severe breathing issues due to emphysema .

The growth of the global emphysema treatment market is expected to be driven by rise in incidence of emphysema and surge in number of smokers globally. Emphysema has been increasingly prevalent across the globe due to surge in geriatric population, alarming rise in environmental pollution, and increase in prevalence of smoking worldwide. For instance, according to 2022 article published by the National Library of Medicine, the prevalence of emphysema in the U.S. is approximately 14 million and is leading COPD disorder across the U.S.

In addition, environmental factors such as air pollution, industrial emissions, and exposure to harmful particulate matter have escalated the risk of developing emphysema, especially in urban areas where pollution levels tend to be higher. The rise in incidence of emphysema globally has resulted in surge in effective therapeutic interventions to manage this chronic disease, which is expected to boost the growth of the global emphysema treatment market.

Furthermore, increase in the number of smokers globally has emerged as a key driving force of the emphysema treatment market. For instance, according to the World Health Organization (WHO) 2021, 22.3% world's population use tobacco with 1.3 million tobacco smokers residing in low- and middle-income countries. With increasing number of individuals adopting smoking habits worldwide, the incidence of emphysema has escalated simultaneously. Smoking is widely recognized as the primary risk factor for developing emphysema, as it leads to the progressive deterioration of lung function and exacerbates existing respiratory conditions. Consequently, the escalating number of smokers has contributed to a heightened demand for effective treatments to manage emphysema-related symptoms and improve patients' quality of life. Thus, rise in number of smokers globally is expected to drive the growth of the market.

The global emphysema treatment market is segmented into treatment type, type, end user, and region. By treatment type, the market is divided into medication, oxygen therapy, and surgery. Depending on type, it is segregated into centriacinar, panacinar, and others. On the basis of end user, it is classified into hospitals, home care, specialty centers, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Novartis AG, Orion Corporation, Viatris Inc., Inogen, Teva Pharmaceuticals, Koninklijke Philips N.V., and Verona Pharma.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2022 to 2032 to identify the prevailing emphysema treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By End User

Hospitals
Homecare
Specialty Centres
Others

By Treatment Type

Medication
- Type
- Bronchodilators
- Steroids
- Others
Oxygen Therapy
Surgery

By Type

Centriacinar
Panacinar
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Viatris Inc.
Koninklijke Philips N.V.
GlaxoSmithKline Plc.
AstraZeneca
Novartis AG
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Inogen, Inc.
Orion Corporation
Verona Pharma Plc.

Product Code: A14372

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of emphysema cases.
  - 3.4.1.2. Surge in number of smokers globally.
  - 3.4.1.3. Increase in air pollution contributing to emphysema.
- 3.4.2. Restraints
  - 3.4.2.1. High cost of treatment.
  - 3.4.2.2. Side effects associated with medications.
- 3.4.3. Opportunities
  - 3.4.3.1. Growth opportunities in emerging markets.

CHAPTER 4: EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Medication
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Medication Emphysema Treatment Market by Type
4.3. Oxygen Therapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Surgery
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: EMPHYSEMA TREATMENT MARKET, BY TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Centriacinar
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Panacinar
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: EMPHYSEMA TREATMENT MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Homecare
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Specialty Centres
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Others
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country

CHAPTER 7: EMPHYSEMA TREATMENT MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Treatment Type
- 7.2.3. Market size and forecast, by Type
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Treatment Type
  - 7.2.5.1.2. Market size and forecast, by Type
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Treatment Type
  - 7.2.5.2.2. Market size and forecast, by Type
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Treatment Type
  - 7.2.5.3.2. Market size and forecast, by Type
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Treatment Type
- 7.3.3. Market size and forecast, by Type
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Treatment Type
  - 7.3.5.1.2. Market size and forecast, by Type
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Treatment Type
  - 7.3.5.2.2. Market size and forecast, by Type
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Treatment Type
  - 7.3.5.3.2. Market size and forecast, by Type
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Treatment Type
  - 7.3.5.4.2. Market size and forecast, by Type
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Treatment Type
  - 7.3.5.5.2. Market size and forecast, by Type
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Treatment Type
  - 7.3.5.6.2. Market size and forecast, by Type
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Treatment Type
- 7.4.3. Market size and forecast, by Type
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Treatment Type
  - 7.4.5.1.2. Market size and forecast, by Type
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Treatment Type
  - 7.4.5.2.2. Market size and forecast, by Type
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Treatment Type
  - 7.4.5.3.2. Market size and forecast, by Type
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Treatment Type
  - 7.4.5.4.2. Market size and forecast, by Type
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Treatment Type
  - 7.4.5.5.2. Market size and forecast, by Type
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Treatment Type
  - 7.4.5.6.2. Market size and forecast, by Type
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Treatment Type
- 7.5.3. Market size and forecast, by Type
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Treatment Type
  - 7.5.5.1.2. Market size and forecast, by Type
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Treatment Type
  - 7.5.5.2.2. Market size and forecast, by Type
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Treatment Type
  - 7.5.5.3.2. Market size and forecast, by Type
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Treatment Type
  - 7.5.5.4.2. Market size and forecast, by Type
  - 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. AstraZeneca
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Boehringer Ingelheim International GmbH
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. GlaxoSmithKline Plc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Viatris Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Novartis AG
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Orion Corporation
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Teva Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Verona Pharma Plc.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Koninklijke Philips N.V.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Inogen, Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments